Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius Medical Care AG & Co. KGaA

Investor Presentation • Mar 20, 2008

165_ip_2008-03-20_b0fe259e-d21a-438c-a5b7-d934bc2b1e49.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Fresenius Medical Care

The World's Leading Renal Therapy Company

Lehman Brothers11th Annual Global Healthcare Conference

March 20, 2008, Miami, Florida

Safe Harbor Statement

This presentation includes certain forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are detailed in the Company's reports filed with the Securities and Exchange Commission and the German Exchange Commission "Deutsche Börse".

1. Business Update

2. Financials and Outlook

3. Midterm Strategy

4. Q&A Session

FY 2007 – Another Record Year

G
i
d
a
n
c
e
u		 F
Y
2
0
0
7
R
e
v
e
n
u
e		 \$
9
5
0
0
m
>
,		 \$
9
7
2
0
m
,
N
i
t
e
n
c
o
m
e		 \$
6
8
5
0
5
7
m
-		 \$
1
7
7
m

Exceededthe Upper End of Guidance

  • X All segments and regions contributed to this excellent result
  • X On track to achieve mid-term target of > US\$ 11.5 billion in revenues by 2010

FY 2007 – Strong Revenue Growth

Total Revenue Increased 14% to \$ 9,720 m *

Dialysis Services - Global

Strong Overall Revenue Growth of 13%cc

\$
i
i
l
l
i
n
m
o
n
s		 F
Y
2
0
0
6		 F
Y
2
0
0
7		 G
h
t
r
o
w		 c
c
1)
N
h
A
i
t
o
r
m
e
r
c
a		 5
3
5
3
,		 5
9
6
2
,		 1
1
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 9
1
3		 1
2
1
1
,		 3
3
%		 2
3
%
1)
T
l
t
o
a		 6
2
6
6
,		 1
3
7
7
,		 1
4
%		 1
3
%

X Continued strong growth in Europe of 12%cc (11% organic), Latin America with 14%cc (14% organic) and Asia-Pacific of 133%cc (11% organic), y-o-y

1) FY 2006 revenue adjusted for sale of perfusion business in the amount of US\$ 111 m and 2007 adjusted for US\$ 40 m cc = constant currency

Dialysis Products - Global

Continued Excellent Growth

\$
i
i
l
l
i
n
m
o
n
s		 F
Y
2
0
0
6		 F
Y
2
0
0
7		 G
h
t
r
o
w		 c
c
T
l
t
o
a
r
e
v
e
n
u
e
(
)
i
l.
I
l
R
t
n
c
n
e
r
n
a
e
v
e
n
u
e		 2
7
7
3
,		 3
2
8
7
,		 1
8
%		 1
2
%
E
l
t
e
r
n
a
r
e
e
n
e
x
v
u		 2
1
2
2
,		 2
5
0
7
,		 1
8
%		 1
2
%
N
h
A
i
t
o
r
m
e
r
c
a		 6
1
5		 6
6
1		 1
8
%		 1
8
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 1
6
0
5
,		 1
8
4
6
,		 1
8
%		 1
0
%

Highlights

N
h
E
(
E
U
)
X
t
u
r
o
p
e
o
r
A
i
m
e
r
c
a
i
i
f
i
(
)
X
A
P
A
P
s
a
a
c
c
-
-		 X
f
Q
I
i
E
B
I
T
i
1
8
%
i
4
0
b
7
7
m
p
r
e
s
s
v
e
m
a
r
g
n
o
n
u
p
p
s
y
-o
-y
X
S
i
i
f
i
d
h
f
i
Q
l
l
b
k
1
7
%
4
t
t
t
t
g
n
c
a
n
p
r
o
c
g
r
o
o
n
e
a
o
e
m
a
r
e
u
w
w
v
X
V
d
l
i
i
d
d
l
i
t
t
t
e
r
y
g
o
o
c
o
s
c
o
n
r
o
n
s
e
r
v
c
e
s
a
n
s
r
o
n
g
u
n
e
r
y
n
g
i
i
t
t
t
p
r
a
e
p
a
o
r
c
o
n
r
a
c
n
g
v
y
E
u
r
o
p
e		 X
S
E
B
I
T
i
d
l
t
t
r
o
n
g
m
a
r
g
n
e
e
o
p
m
e
n
v
X
O
i
h
f
f
F
Y
8
%
t
r
g
a
n
c
r
e
v
e
n
u
e
g
r
o
w
o
+
o
r
X
0
0
8
H
D
M
h
i
i
l
6
%
f
F
Y
5
7
t
a
c
n
e
n
s
a
e
s
p
-o
o
r
u
u
y
-y
X
B
d
l
d
f
h
d
i
l
i
i
P
l
t
t
t
t
t
u
n
e
r
a
e
p
e
r
r
e
a
m
e
n
o
r
e
m
o
a
y
s
s
n
o
r
u
g
a
A
i
s
a
i
f
i
P
a
c
c		 X
P
d
l
h
f
F
Y
f
1
%
5
t
t
r
o
c
s
s
a
e
s
g
r
o
o
r
o
+
c
c
-o
u
w
y
-y
X
R
h
i
C
h
i
f
f
F
Y
2
1
%
t
e
v
e
n
u
e
g
r
o
w
n
n
a
o
+
c
c
y
-o
-y
o
r
X
S
h
(
l.
E
l
i
)
f
F
Y
1
2
1
%
1
7
%
t
t
t
t
t
r
o
n
g
r
e
a
m
e
n
g
r
o
+
e
c
c
e
s
o
r
o
r
w
x
x

FY = Fiscal Year

Financials and Outlook

1) Profit & Loss

\$
i
i
l
l
i
n
m
o
n
s		 F
Y
2
0
0
6		 F
Y
2
0
0
7		 G
h
t
r
o
w
*
N
t
e
r
e
e
n
e
v
u		 8
4
9
9
,		 9
2
0
7
,		 1
4
%
2)
O
(
)
i
i
E
B
I
T
t
p
e
r
a
n
g
n
c
o
m
e		 1
3
1
5
,		 5
1
8
0
,		 2
0
%
E
B
I
T
i
i
%
m
a
r
g
n
n		 1
5
5		 1
6.
3
2)
I
t
t
t
n
e
r
e
s
e
p
e
n
s
e,
n
e
x		 3
3
7		 3
1
7
2)
I
b
f
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 9
7
8		 1
2
0
9
,		 2
4
%
2)
I
T
n
c
o
m
e
a
x
e
x
p
e
n
s
e		 3
8
7		 4
6
6
T
t
a
x
r
a
e		 4
0
%		 3
9
%
M
i
i
i
t
t
t
n
o
r
y
n
e
r
e
s		 1
7		 2
6
2)
N
i
t
e
n
c
o
m
e		 4
5
7		 1
7
7		 2
%
5

* 12% growth at constant currency, 6% organic growth

1) Excluding one-time items in 2006

2) A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

Cash Flow

\$
i
i
l
l
i
n
m
o
n
s		 F
Y
2
0
0
6		 F
Y
2
0
0
7		 G
h
t
r
o
w
1)
N
h
i
d
d
b
i
i
i
i
t
t
t
t
e
c
a
s
p
r
o
v
e
y
o
p
e
r
a
n
g
a
c
v
e
s		 1
1
0
6
,		 1
2
0
0
,
1
2.
3
%
f r
o
ev
en
ue		 9
%
1)
C
i
l
d
i
t
t
(
)
a
p
a
e
x
p
e
n
u
r
e
s
t
n
e		 (
)
4
0
5		 (
)
5
4
9
C
F
h
F
l
r
e
e
a
s
o
w		 6
5
6		 5
6
1
1)
A
i
i
i
f
d
i
i
t
t
t
t
c
q
s
o
n
s
n
e
o
e
s
r
e
s
u
v
u
,		 (
)
1
9
5		 (
)
2
2
8
C
F
h
F
l
r
e
e
a
s
o
w
f
i
i
i
t
t
a
e
r
a
c
q
s
o
n
s
u		 4
9
7		 4
2
3
C
F
h
F
l
r
e
e
a
s
o
w
f
S
i
i
i
l
d
i
R
I
t
t
a
e
r
a
c
q
s
o
n
s
e
c
n
g
u
x
u		 4
9
7		 5
4
3

1) A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

Debt / EBITDA Development

De-leveraging ahead of schedule

Debt / EBITDA Development

Summary – 2008 Growth Drivers

N
h
t
o
r
A
i
m
e
r
c
a		 E
r
o
p
e
u		 A
i
s
a
f
P
i
i
a
c
c
R
l
P
h
e
n
a
a
r
m
a		 9 9
C
E
i
f
l
i
i
N
k
t
x
p
a
n
s
o
n
o
n
c
e
w
o
r		 9 9 9
Q
R
i
b
B
d
l
i
t
t
e
m
r
s
e
m
e
n
a
s
e
o
n
a
u
u
y		 9 9 9
S
I
d
P
d
M
k
h
t
t
n
c
r
e
a
s
e
r
o
u
c
a
r
e
a
r
e		 9 9

Targeted Revenue Growth >7%

Outlook 2008

\$
i
i
l
l
i
n
m
o
n
s		 G
i
d
u
a
n
c
e
N
R
t
e
e
e
n
e
s
v
u		 \$
1
0
4
0
0
>
,
N
I
t
e
n
c
o
m
e		 \$
5
5
8
0
8
2
-
L
i
t
e
v
e
r
a
g
e
r
a
o
(
D
b
/
E
B
I
T
D
A
)
t
e		 2
8
<
C
i
l
E
d
i
t
t
a
p
a
p
e
n
r
e
x
u		 \$
5
5
6
0
7
0
~
-
A
i
i
i
t
c
q
u
s
o
n
s		 \$
1
5
0
2
5
0
~
-

X Another strong year ahead

X Increased investment budget driven by further growth opportunities

Fresenius Medical Care

Midterm Strategy

Growth in Number of Dialysis Patients – Worldwide

  • •Renal failure persists as a chronic worldwide epidemic
  • •Dialysis is the primary treatment modality for renal failure on a global scale
  • • Exponential growth trend continues on a global scale as incidence (new cases) and patient survival improve.

Sustainable Patient Growth of 5-6% p.a.

~ 2 Million Patients Worldwide by 2010

Market Opportunity

Leader in Products Worldwide

\$9.8 Billion Products Market

Integrated Patient Care Model – Clinic Centric

2010 Revenue Target

Sustainable Growth of Earnings After Tax – Low to Mid-Teens per year

Outlook 2010

Thank You for your interest in Fresenius Medical Care !

Q&A Session

Fresenius Medical Care

The World's Leading Renal Therapy Company

Lehman Brothers11th Annual Global Healthcare Conference

March 20, 2008, Miami, Florida

Dialysis Services - Global

F
Y
2
0
0
7		 C
l
i
i
n
c		 P
i
t
t
a
e
n
s		 T
t
t
r
e
a
m
e
n
s
(
)
in
i
l
l
ion
m
T
l
t
o
a		 2
2
3
8
,		 1
7
3
8
6
3
,		 2
6
4
G
h
t
r
o
w		 6
%
+		 6
%
+		 1
1
%
+
N
h
A
i
t
o
r
m
e
r
c
a		 1
6
0
2
,		 1
2
1
4
3
1
,		 1
8
5
G
h
t
r
o
w		 3
%
+		 3
%
+		 9
%
+
I
i
l
t
t
n
e
r
n
a
o
n
a		 6
3
6		 5
2
4
3
2
,		 8
0
G
h
t
r
o
w		 1
6
%
+		 1
%
5
+		 1
6
%
+
E
u
r
o
p
e		 3
6
2		 2
6
9
0
2
,		 4
1
L
i
A
i
t
a
n
m
e
r
c
a		 1
6
9		 1
4
1
7
7
,		 2
7
A
i
P
i
f
i
s
a-
a
c
c		 1
0
5		 7
7
8
9
,		 1.
2

Attachment I

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

D
b
t
e		 F
Y
2
0
0
7		 F
Y
2
0
0
6		 F
Y
2
0
0
5		 F
Y
2
0
0
4		 F
Y
2
0
0
3
1)
S
/
ho
bo
ing
(
inc
l.
A
R
)
t
te
r
rm
rro
w
s
p
ro
g
ra
m		 2
1
7		 3
3
1		 1
5
1		 4
1
9		 9
0
S
ho
bo
ing
fro
la
d p
ies
t
te
te
t
r
rm
rro
s
m
re
ar
+
w		 2 5 1
9		 6 3
0
Cu
ion
f
lon
de
b
d c
i
l
lea
b
l
ig
ion
t p
t
te
t a
ta
t
rre
n
or
o
g-
rm
n
ap
se
o
a
s
+		 8
5		 1
6
0		 1
2
6		 2
3
0		 9
0
Cu
ion
f
Tr
Pr
fe
d
Se
i
ies
t p
t
t
t
+
rre
n
or
o
us
e
rre
cu
r		 6
7
0
Lo
-te
de
b
t a
d c
i
ta
l
lea
b
l
ig
t
ion
les
t p
t
ion
ng
rm
n
ap
se
o
a
s,
s c
ur
re
n
or
+		 4,
0
0
4		 3,
8
2
9		 7
0
7		 5
4
5		 1,
1
1
2
Tr
Pr
fe
d
Se
i
ies
(
f c
ion
)
t
t
t o
t p
t
us
e
rre
cu
r
ne
ur
re
n
or
+		 6
6
4		 1,
2
5
4		 1,
1
8
8		 1,
2
7
9		 1,
2
4
2
Ac
iva
b
le
i
iza
ion
ts
t
t
co
un
rec
e
se
cu
r
p
ro
g
ra
m
+		 0 0 0 0 1
5
8
To
l
de
b
ta
t
=		 5,
6
4
2		 5,
5
7
9		 2,
1
9
1		 2,
4
7
9		 2,
7
2
2

All numbers are in \$ millions

E
B
I
T
D
A		 F
Y
2
0
0
7		 2)
F
Y
2
0
0
6
(pr
o f
)
orm
a		 F
Y
2
0
0
5		 F
Y
2
0
0
4		 F
Y
2
0
0
3
La
lve
hs
ing
inc
(
E
B
I
T
)
t
tw
t
t
s
e
m
on
o
p
er
a
om
e		 1,
5
8
0		 1,
3
6
7		 9
3
9		 8
5
2		 5
7
7
La
lve
hs
de
ia
ion
d a
iza
ion
t
tw
t
t
t
t
s
e
m
on
p
rec
an
mo
r
+		 3
6
3		 3
2
6		 2
5
1		 2
3
3		 2
1
6
No
h c
ha
n-c
as
rg
es
+		 4
1		 3
5		 1
4		 1
3		 1
3
E
B
I
T
D
A
(
l
ize
d
)
an
nu
a
=		 1,
9
8
4		 1,
2
8
7		 1,
2
0
4		 1,
0
9
8		 9
8
6

1) A/R securitization program off-balance sheet in 2003 and included in short term borrowings from 2004 onwards 2) Excluding restructuring costs and in-process R&D

Attachment II

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

All numbers are in \$ millions

E
l
R
t
e
r
n
a
e
e
n
e
x
v
u		 F
Y
2
0
0
7		 F
Y
2
0
0
6		 h
t
g
row		 cc Q
4
2
0
0
7		 Q
4
2
0
0
6		 h
t
g
row		 cc
In
io
l
du
te
t
t r
rn
a
na
p
ro
c
ev
en
ue		 2,
0
9
9		 1,
7
4
9		 2
0
%
+		 1
1
%
+		 6
0
8		 5
0
1		 2
1
%
+		 9
%
+
In
l re
te
rna
ve
nu
e
-		 (
)
2
5
3		 (
)
1
8
9		 (
)
7
5		 (
)
5
1
Ex
l r
te
rn
a
ev
en
ue
=		 1,
8
4
6		 5
1,
6
0		 1
8
%
+		 1
0
%
+		 5
3
3		 5
4
0		 1
8
%
+		 7
%
+
No
h
Am
ica
du
t
t r
r
er
p
ro
c
ev
en
ue		 1,
1
7
9		 1,
0
2
4		 1
5
%
+		 3
1
0		 2
8
4		 9
%
+
In
l re
te
rna
ve
nu
e
-		 (
)
5
1
8		 (
)
4
6
3		 (
)
1
3
0		 (
)
1
3
1
Ex
l r
te
rn
a
ev
en
ue
=		 6
6
1		 5
6
1		 1
8
%
+		 1
8
0		 5
1
3		 1
7
%
+
T
O
T
A
L
du
t r
p
ro
c
ev
en
ue		 3,
2
8
7		 2,
3
7
7		 1
8
%
+		 1
2
%
+		 9
1
8		 8
7
5		 1
%
7
+		 9
%
+
In
l re
te
rna
ve
nu
e
-		 (
)
7
7
1		 (
)
6
5
1		 (
)
2
0
5		 (
)
1
8
2
Ex
l r
te
rn
a
ev
en
ue
=		 2,
5
0
7		 2,
1
2
2		 1
8
%
+		 1
2
%
+		 7
1
3		 6
0
3		 1
8
%
+		 1
0
%
+
C
(
)
i
l
d
i
t
t
t
a
p
a
e
x
p
e
n
u
r
e
n
e		 F
Y
2
0
0
7		 F
Y
2
0
0
6		 Q
4
2
0
0
7		 Q
4
2
0
0
6
Pu
ha
f p
lan
d
ip
ty
t a
t
rc
se
o
ro
p
er
p
n
eq
u
m
en
,		 5
8
0		 4
6
7		 1
9
4		 1
7
9
Pr
ds
fro
le
f p
lan
d
ip
ty
t a
t
oc
ee
m
sa
o
ro
p
er
p
n
eq
u
m
en
-
,		 (
3
1
)		 (
1
)
7		 (
1
0
)		 (
2
)
Ca
i
l e
d
i
(
)
ta
tu
t
p
xp
en
re
ne
=		 4
9
5		 4
0
5		 1
8
4		 1
7
7

cc = constant currency

Attachment III

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

All numbers are in \$ millions

O
i
f
b
f
i
i
t
t
t
p
e
r
a
n
g
p
e
r
o
r
m
a
n
c
e
e
o
r
e
o
n
e-
m
e
e
m
s		 F
Y
2
0
0
7		 F
Y
2
0
0
6		 h
t
g
row		 Q
4
2
0
0
7		 Q
4
2
0
0
6		 h
t
g
row
Op
ing
inc
(
E
B
I
T
)
t
er
a
om
e		 1,
8
0
5		 1,
3
1
8		 2
0
%		 4
2
8		 3
4
5		 2
1
%
in
fro
ive
i
in
in
Ga
d
R
&
D
t
tu
tru
tu
m
s
re
re
s
c
r
g
-p
ro
ce
ss
+
+		 - (
)
3		 - 2
5
Op
(
)
ing
inc
E
B
I
T
be
fo
im
i
t
t
te
er
a
om
e
re
on
e-
e-
ms		 1,
5
8
0		 1,
3
1
5		 2
0
%		 4
2
8		 3
7
9		 1
3
%
in
Ne
t
co
m
e		 7
1
7		 5
3
7		 3
4
%		 1
9
7		 1
5
2		 3
0
%
fro
ive
i
in
in
Lo
d
t
tu
tru
tu
R
&
D
ss
m
s
re
re
s
c
r
g
-p
ro
ce
ss
+
,		 - 3
7		 - 1
8
fo
Ne
inc
be
im
i
t
t
te
om
e
re
on
e-
e-
ms		 7
1
7		 5
7
4		 2
5
%		 1
9
7		 1
7
0		 1
6
%
P
f
i
&
L
A
t
t
r
o
o
s
s
c
c
o
u
n		 Q
4
2
0
0
6		 On
im
i
t
tem
e-
e
s		 Q
4
2
0
0
6
lu
d
ing
im
i
t
tem
ex
c
on
e-
e
s
Ne
t r
ev
en
ue		 2,
3
5
2		 2,
3
5
2
Op
in
in
(
E
B
I
T
)
t
er
a
g
co
me		 3
5
4		 *
2
5		 3
9
7
E
B
I
T-
in
(
)
%
m
ar
g		 1
5.
0		 1
6.
1
In
te
t e
t
res
xp
en
se
ne
,		 (
)
9
6		 (
)
9
6
In
be
fo
in
ta
co
m
e
re
co
m
e
xe
s		 2
5
8		 2
5		 2
8
3
Inc
Ta
om
e
x e
xp
en
se		 (
)
9
9		 (
)
7		 (
)
1
0
6
(
)
Ta
%
te
x r
a		 3
8		 3
8
M
ino
i
in
ty
te
t
r
res		 (
)
7		 (
)
7
Ne
in
t
co
m
e		 5
1
2		 1
8		 1
7
0

* Restructuring costs of US\$ 22 m and US\$ 3 m in process R&D

Attachment IV

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

All numbers are in \$ millions

P
f
i
&
L
A
t
t
r
o
o
s
s
c
c
o
u
n		 F
Y
2
0
0
6		 On
im
i
t
tem
e-
e
s		 F
Y
2
0
0
6
lu
d
ing
t
im
i
tem
ex
c
on
e-
e
s
Ne
t r
ev
en
ue		 8,
4
9
9		 8,
4
9
9
Op
in
in
(
E
B
I
T
)
t
er
a
g
co
me		 1,
3
1
8		 *
(
3
)		 1,
3
1
5
E
B
I
T-
in
(
%
)
m
ar
g		 1
%
5.
5		 1
%
5.
5
In
te
t e
t
res
xp
en
se
ne
,		 (
)
3
5
1		 **
1
4		 (
)
3
3
7
In
be
fo
in
ta
co
m
e
re
co
m
e
xe
s		 9
6
7		 1
1		 9
7
8
Inc
Ta
om
e
x e
xp
en
se		 (
)
4
1
3		 2
6		 (
)
3
8
7
(
)
Ta
%
te
x r
a		 4
3
%		 4
0
%
M
ino
i
in
ty
te
t
r
res		 (
1
7
)		 (
1
7
)
Ne
in
t
co
m
e		 5
3
7		 3
7		 5
4
7
O
i
i
N
h
A
i
t
t
p
e
r
a
n
g
n
c
o
m
e
o
r
m
e
r
c
a		 Q
4
2
0
0
6		 F
Y
2
0
0
6
Re
ve
nu
e		 1,
6
5
8		 6,
0
2
5
Op
ing
inc
(
E
B
I
T
)
t
er
a
om
e		 2
6
0		 9
6
5
E
B
I
T
in
(
in
%
f r
)
m
ar
g
o
ev
en
ue		 1
5.
%
7		 1
6.
0
%
On
im
i
t
te
e-
e-
m
s		 2
4		 (
)
7
E
B
I
T
in
(
in
%
f r
)
be
fo
im
i
-t
te
m
ar
g
o
ev
en
ue
re
o
ne
e
m
s		 1
7.
1
%		 1
5.
9
%

* US\$ 40 m gain from divestiture, less US\$ 32 m restructuring costs, US\$ 3 m in process R&D and US\$ 2 m costs for transformation of the legal form of the Company

** Write-off of deferred financing costs

Attachment V

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

All numbers are in \$ millions

C
h
F
l
a
s
o
w		 Q
4
2
0
0
7		 F
Y
2
0
0
7
Ac
is
i
ion
t
q
u
s		 (
1
1
8
)		 (
2
8
)
5
Pr
ds
fro
d
ive
i
t
tu
oc
ee
m
s
res		 - 3
0
Ac
is
i
io
f
d
ive
i
t
t o
t
tu
q
ns
ne
s
re
s
u
,		 (
)
1
1
8		 (
)
2
2
8
C
h
F
l
a
s
o
w		 Q
4
2
0
0
6		 Ta
for
ts
x p
ay
me
n
ior
p
r
y
ea
rs		 C
G
R
is
i
ion
t
ac
q
u		 Q
4
2
0
0
6
Ne
h
i
de
d
by
in
iv
i
ies
t c
t
t
t
as
p
ro
v
o
p
er
a
g
ac		 4
4
3		 4
4
3
Ca
i
l
Ex
d
i
(
)
ta
tu
t
p
p
en
res
ne		 (
)
1
7
7		 (
)
1
7
7
Fr
Ca
h
F
low
ee
s		 2
6
6		 - 2
6
6
Ac
is
i
ion
d
d
ive
i
t
t
tu
q
u
s a
n
s
res		 (
)
1
0
9		 (
)
6		 (
)
1
1
5
Fr
Ca
h
F
low
f
is
i
io
d
d
ive
i
te
t
t
tu
ee
s
a
r a
cq
u
ns
a
n
s
re
s		 1
5
7		 - (
)
6		 1
5
1
C
h
F
l
a
s
o
w		 F
Y
2
0
0
6		 for
Ta
ts
x p
ay
me
n
ior
p
r
y
ea
rs		 C
G
R
is
i
t
ion
ac
q
u		 F
Y
2
0
0
6
Ne
h
i
de
d
by
in
iv
i
ies
t c
t
t
t
as
p
ro
o
p
er
a
g
ac
v		 9
0
8		 9
9		 9
9		 1,
1
0
6
Ca
i
l
Ex
d
i
(
)
ta
tu
t
p
p
en
res
ne		 (
)
4
5
0		 (
)
4
5
0
Fr
Ca
h
F
low
ee
s		 4
5
8		 9
9		 9
9		 6
5
6
Ac
is
i
ion
d
d
ive
i
t
t
tu
q
u
s a
n
s
res		 (
3,
9
1
)
7		 3,
6
3
2		 (
1
9
)
5
Fr
Ca
h
F
low
f
is
i
io
d
d
ive
i
te
t
t
tu
ee
s
a
r a
cq
u
ns
a
n
s
re
s		 (
3,
3
3
3
)		 9
9		 3,
3
1
7		 4
9
7

Contacts

Fresenius Medical Care AG & Co. KGaAInvestor RelationsElse Kröner Str. 161352 Bad Homburg v.d.H.

Ordinary shares WKN 578 580ISIN DE0005785802SEDOL1 5129074 DE

Oliver MaierHead of Investor Relations & Corporate Communications Tel.: +49-(0)6172-609-2601 Fax.: +49-(0)6172-609-2301 Email: [email protected]

Terry L. Morris Tel.: +1-800-948-2538Fax.: +1-615-345-5605Email: [email protected]

Gerrit JostTel.: +49-(0)6172-609-5216 Fax.: +49-(0)6172-609-2301

Email: [email protected]

Reminder …

For recent updates, please have a look at our webpage. Navigation around

www.fmc-ag.com

CalendarInvestor Relations > Financial Calendar

Annual Report / Quarterly Filings / SEC Filings / Deutsche Börse Filings ... Investor Relations > Publications

Corporate Governance / Sarbanes-Oxley Act / NYSE declaration ... Investor Relations > Corporate Governance

Financing / Analyst Coverage / Consensus estimates / Share data … Investor Relations > Our Share

More from Fresenius Medical Care AG & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2026
Jan 16
Share Issue/Capital Change 2026
Jan 12
Transaction in Own Shares 2026
Jan 9
Share Issue/Capital Change 2025
Dec 29
AGM Information 2025
Dec 22
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 15
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 12
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 8
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 3
Transaction in Own Shares 2025
Dec 1
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.